Related Experiment Videos

Polymeric delivery of the active isomer of misoprostol reduces systemic availability and uterotonic activity

G W Gullikson1, R F Loeffler, D V Mehrotra

  • 1Department of Neurological Diseases Research, G. D. Searle and Co., Skokie, Illinois, USA.

Insights

SC-55307, a novel delivery system for misoprostol

Area of Science:

  • Pharmacology
  • Gastroenterology
  • Reproductive Endocrinology

Background:

  • SC-30249, the active isomer of misoprostol, provides mucosal protection against NSAIDs.
  • A novel polymer-linked delivery system, SC-55307, releases SC-30249 under acidic stomach conditions.
  • This targeted delivery aims to minimize side effects and systemic exposure of synthetic prostaglandins.

Purpose of the Study:

  • To evaluate the uterotonic activity of SC-55307, a prostaglandin delivery system.
  • To assess potential prostaglandin-related side effects on uterine activity.
  • To compare uterotonic responses to SC-55307 versus free SC-30249.

Main Methods:

  • Female beagles were surgically fitted with uterine strain gauge force transducers.
  • Estrogen treatment sensitized the uterus to prostaglandin effects.
  • Uterine responses to intravenous SC-30249, oral SC-30249, and oral SC-55307 (low and high doses) were measured.

Main Results:

  • A high dose of SC-55307 induced a brief, statistically significant increase in uterine activity (8.8-17.8% of SC-30249 response).
  • Low-dose SC-55307 showed no significant uterotonic effect.
  • Peak plasma concentrations of SC-30249 free acid were substantially lower with SC-55307 compared to free SC-30249 administration.

Conclusions:

  • SC-55307 demonstrates minimal uterotonic activity, suggesting reduced systemic prostaglandin effects.
  • The polymer-linked delivery system effectively limits systemic availability of SC-30249.
  • SC-55307 shows potential for targeted mucosal protection with a favorable side effect profile.

Related Concept Videos